Sun Pharmaceutical Industries · NSE: SUNPHARMA · BSE: 524715
Q1 FY23 results · Apr–Jun 2022
Sun Pharmaceutical Industries reported revenue from operations of ₹10,761.76 crore (up 10.7% from Q1 FY22) and net profit of ₹2,093.39 crore (up 49.1% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a consolidated basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 10,761.76 | 9,718.74 | +10.7% | 9,446.76 | +13.9% |
| Other income | 2.14 | 152.52 | −98.6% | 113.59 | −98.1% |
| Total income | 10,763.90 | 9,871.26 | +9.0% | 9,560.35 | +12.6% |
| Profit before share of associates & JVs and tax | 2,284.84 | 1,804.22 | +26.6% | (2,075.60) | Turned profit |
| Share of profit/(loss) of associates & JVs | (2.46) | (4.61) | (5.02) | ||
| Net profit for the period | 2,093.39 | 1,404.04 | +49.1% | (2,227.38) | Turned profit |
| Attributable to shareholders of the company | 2,060.88 | 1,444.17 | +42.7% | (2,277.25) | Turned profit |
| EPS, basic (₹) | 8.60 | 6.00 | +43.3% | (9.50) | Turned profit |
| Net margin (%) | 19.5 | 14.4 | -23.6 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 4,932.88 | 3,325.95 | +48.3% | 4,006.88 | +23.1% |
| Other income | 48.99 | 57.80 | −15.2% | 300.41 | −83.7% |
| Total income | 4,981.87 | 3,383.75 | +47.2% | 4,307.29 | +15.7% |
| Profit before tax | 1,037.08 | 432.65 | +139.7% | (800.04) | Turned profit |
| Net profit for the period | 1,011.80 | 419.30 | +141.3% | (1,286.21) | Turned profit |
| EPS, basic (₹) | 4.20 | 1.75 | +140.0% | (5.40) | Turned profit |
| Net margin (%) | 20.5 | 12.6 | -32.1 |
Consolidated
- Filed with BSE
- 30 Jul 2022, 09:33 IST
- Board meeting
- 29 Jul 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Jul 2022, 09:33 IST
- Board meeting
- 29 Jul 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE